MDMarie Pia D'ORtho

Marie Pia D'ORtho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marie Pia D'ORtho has a total of 190 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Implementation of a WatchPAT‐Based Diagnostic Pathway for Obstructive Sleep Apnea in a Tertiary Hypertension Center: A Feasibility Study

    by Alexandre Boutigny, Justina Motiejunaite, Pauline Balagny, Florence Arnoult, Emmanuelle Vidal‐Petiot, Nassim Mohamedi, Justine Frija, Marie‐Pia D’ORtho

    Background: Obstructive sleep apnea (OSA) is a prevalent yet underdiagnosed in hypertension, affecting 30% to 83% of patients. Limited polysomnography access delays diagnosis. We evaluated the feasibility, diagnostic yield, and downstream management decisions of an integrated diagnostic pathway using WatchPAT 300, a peripheral arterial tonometry‐based home sleep apnea test, in a tertiary hypertension unit. Methods: In this single‐center, prospective, observational study, 200 patients underwent ambulatory OSA assessment from May 2023 through August 2025. We recorded clinical variables, peripheral arterial tonometry data, and management decisions. A subgroup underwent confirmatory in‐laboratory polysomnography. Patients were classified as none‐to‐mild OSA (peripheral apneahypopnea index <15/h) and moderate‐to‐severe OSA (≥15/h). Results: The pathway achieved 97.5% (95% CI, 94%–99%) technical success and reduced the mean time‐to‐diagnosis to 3.5±4.5 days, versus 154 days for in‐laboratory polysomnography. Over half of the cohort was triaged: ∼30% met treatment criteria directly, and 22% were ruled out. Among patients completing confirmatory polysomnography, 83% (95% CI, 61%–94%) initially classified as none‐to‐mild were reclassified as moderate‐to‐severe OSA, and 77% required treatment. Furthermore, symptoms were dissociated from severity, and Snoring‐Tired‐Observed‐Pressure‐BMI‐Age‐Gender (STOP‐Bag) association with severity did not remain significant after multiplicity correction. Conclusions: A peripheral arterial tonometry‐based home sleep apnea test‐first model is feasible and efficient, eliminating diagnostic delays. Although effective for triaging clear‐cut cases, the high reclassification rate underscores the almost mandatory role of confirmatory polysomnography for milder or equivocal results, suspected comorbid sleep disorders, or high STOP‐Bag score. These data argue against symptoms‐based screening alone to screen populations with hypertension.

  • Open Access

    Mafb-lineage activation of a short polyalanine (+5) PHOX2B mutation produces severe respiratory dysfunction with preserved postnatal weight gain among survivors in a mouse model of congenital central hypoventilation syndrome

    by Nelina Ramanantsoa, Charline Riaud, Amelia Madani, Pauline Andres, Thomas Bourgeois, Jean-Luc Mandaba, Laura Cardoit, Jean Forgue, Nathaly Romero, Manon Perrain, et al.

    Rationale: Congenital central hypoventilation syndrome (CCHS) is most commonly caused by polyalanine repeat mutations in PHOX2B. The in vivo consequences of the short five-alanine expansion and the contribution of specific hindbrain lineages to the resulting respiratory phenotype remain poorly understood. Objectives: To characterize the neonatal phenotype caused by the Phox2b 25Ala/+ mutation and determine the contribution of the MafB lineage associated with the r5–r6 hindbrain territory. Methods: We generated a conditional Phox2b 25Ala allele and studied mice with constitutive or MafB-lineage activation. Neonatal survival, growth, gastric milk content, ventilation, and hypercapnic responses were assessed in vivo . Respiratory-network activity and responses to extracellular acidification were recorded in E18.5 isolated brainstem–spinal cord preparations, and retrotrapezoid nucleus (RTN) development was examined histologically. Measurements and Main Results: Constitutive Phox2b 25Ala/+ pups exhibited high neonatal mortality, markedly impaired weight gain, reduced gastric milk scores, hypoventilation, increased apnea time, and blunted ventilatory responses to CO₂. Embryonic preparations showed a slower respiratory rhythm, an impaired response to acidification, and severe RTN dysgenesis. Activation of the mutant allele in the MafB lineage was also associated with severe respiratory dysfunction, RTN dysgenesis, and early neonatal mortality. In contrast, postnatal weight gain was preserved among surviving MafB-lineage mutants, and the reduction in gastric milk scores was significantly attenuated compared with constitutive mutants. Conclusions: A short PHOX2B polyalanine expansion reproduces major respiratory features of CCHS in mice. Activating the mutant allele in the MafB lineage is sufficient to cause severe respiratory dysfunction and neonatal mortality, whereas postnatal weight gain is preserved among survivors.

  • Open Access

    Evaluation of the Clinical Performance of a Chest-Worn Smartphone-based Medical Device for Sleep Apnea-Hypopnea Syndrome Diagnosis: The EASY Study

    by Justine Frija, Thi Ngoc Bich Diep, Maria Trinidad Díaz-Cambriles, Wojciech Trzepizur, A. Abad Fernández, Ala Covali, Jean-Arthur Micoulaud-Franchi, Anja Seiger, Simon Gaudier, Claire Launois, et al.

    Background: Systems that record sounds and inertial signals from a smartphone placed on the thorax have the potential to increase access to sleep-apnoea diagnosis, but evaluations against polysomnography (PSG) are lacking. The EASY study evaluated the diagnostic performance of Apneal®, a smartphone Software as a Medical Device, to estimate the apnea–hypopnea index (AHI) and detect clinically relevant AHI thresholds compared with PSG.Methods: Prospective, multicentre clinical study in nine European sleep centres. Adults referred for diagnostic overnight PSG had in-lab PSG (central scoring) and simultaneous Apneal® v1.0.0 with Apneal® AI v1.3.1 recording with a consumer smartphone secured to the chest using an adhesive band. The primary objective was diagnostic performance at AHI thresholds (≥5, ≥15, ≥30 events/hour) versus PSG ; secondary objectives included continuous AHI agreement, comparison to polygraphy and nocturnal oximetry. The statistical analysis plan was prespecified; main diagnostic metrics reported are sensitivity, specificity, positive and negative predictive values (PPV, NPV), and area under the ROC curve (AUC) with 95% CIs.Findings: 491 participants were enrolled, and 432 analyzed. Apneal® severity classification versus adjudicated PSG had a quadratic-weighted κ = 0.88 (95% CI 0.83–0.92). At prespecified binary thresholds: for AHI ≥5 sensitivity 97% (95% CI 95–98), specificity 78% (61–89), PPV 98% (96–99), NPV 70% (54–83); for AHI ≥15 sensitivity 91% (87–94), specificity 91% (85–94), PPV 93% (89–96), NPV 88% (82–92); for AHI ≥30 sensitivity 84% (77–90), specificity 95% (92–97), PPV 88% (81–93), NPV 94% (90–96).Interpretation: Apneal® — a smartphone placed on the thorax and processed by a locked AI pipeline — provided accurate AHI estimates and high discrimination for clinically relevant thresholds compared with adjudicated PSG in a large, multicentre, real-world population. Performance was robust across the spectrum of severity.

  • Open Access

    A Sleep and Circadian Biomarker‐Based Predictive Model for Differentiating Unipolar and Bipolar Depression

    by Jeanne Leseur, Pierre A. Geoffroy, Anne Perozziello, Delfine Abderrahmane, Héloïse Rach, Michel Lejoyeux, Marie Pia D’ORtho, Justine Frija, Julia Maruani

    Background/Study Objectives: Differentiating unipolar depression (UDD) from bipolar depression (BDD) remains a major clinical challenge with important treatment implications. Sleep‐related markers, both subjective (such as hypersomnia in BDD and insomnia in UDD) and objective (actigraphy, polysomnography [PSG]), show promise, yet no study has integrated these approaches into a single predictive model. Methods: Patients with DSM‐5‐TR‐defined UDD or BDD in a depressive episode underwent clinical, questionnaire, actigraphy, and PSG assessments. Discriminating variables were entered into a backward stepwise logistic regression (BSLR) to derive the optimal classification model. Results: The study drew on 159 patients: 43 with BDD (42 actigraphy, 20 PSG) and 116 with UDD (93 actigraphy, 44 PSG). Compared to BDD, patients with UDD reported poorer sleep quality (Pittsburgh sleep quality index [PSQI]), more severe insomnia (insomnia severity index [ISI]), and lower sleep efficiency (SE, actigraphy). Patients with BDD showed longer total rest time per 24 h, lower average activity during the least active 5‐h period (L5) and the 10 most active hours (M10), and higher N2% and total NREM sleep (PSG). Six variables were retained in the final BSLR model, explaining 49.4% of the variance. The most discriminative were higher PSQI/ISI and lower actigraphic SE in UDD, versus longer rest time, lower L5 activity, and higher N2% in BDD. The model showed excellent discriminative ability (AUC = 0.926, sensitivity = 0.882, specificity = 0.895, Youden’s index = 0.777), with strong predictive values (positive predictive value [PPV] = 88.3%, negative predictive value [NPV] = 89.5%). Conclusion: Integrating subjective, actigraphic, and polysomnographic markers provides a promising, noninvasive approach to differentiate UDD from BDD.

  • Open Access

    Proposition of a new, minimally-invasive, software smartphone device to predict sleep apnea and its severity

    by Justine Frija, Juliette Millet, Emilie Béquignon, Ala Covali, Guillaume Cathelain, Josselin Houenou, Hélène Benzaquen, Pierre A. Geoffroy, Emmanuel Bacry, Mathieu Grajoszex, et al.

    Purpose obstructive sleep apnea is underdiagnosed due to limited access to polysomnography (PSG). We aimed to assess the performances of Apneal®, an application recording sound and movements thanks to a smartphone’s microphone, accelerometer and gyroscope, to estimate patients’ apnea-hypopnea index (AHI). Methods monocentric proof-of-concept study with a first manual scoring step, then automatic detection of respiratory events from recorded signals using a sequential deep-learning model (version 0.1 of Apneal® automatic scoring of respiratory events, end 2022), in adult patients. Results 46 patients (women 34%, BMI 28.7 kg/m²) were included. Sensitivity of manual scoring was 0.91 (95% CI [0.8-1]) for IAH > 15 and 0.85 [0.67-1] for AHI > 30, and positive predictive values (PPV) 0.89 [0.76–0.97] and 0.94 [0.8-1]. We obtained an AUC-ROC of 0.85 (95% CI [0.69–0.96]) and AUC-PR of 0.94 (95% CI [0.84–0.99]) for the identification of AHI > 15, and AUC-ROC of 0.95 [0.860.99] and AUC-PR of 0.93 [0.81–0.99] for AHI > 30. The ICC between the AHI estimated manually, and from the PSG is 0.89 (p = 6.7 × 10− 17), Pearson correlation 0.90 (p = 1.25 × 10− 17). Automatic scoring found sensitivity of 1 [0.95-1], PPV of 0.9 [0.8–0.9] for AHI > 15, and sensitivity 0.95 [0.84-1], PPV 0.69 [0.52–0.85] for AHI > 30. The ICC between the estimated AHI, and PSG scorings is 0.84 (p = 5.4 × 10− 11) and Pearson correlation is 0.87 (p = 1.7 × 10− 12). Conclusion Manual scoring of smartphone-based signals is possible and accurate compared to PSG-based scorings. Automatic scoring method based on a deep learning model provides promising results. Trial registration NCT03803098.


  • Neonatal obstructive sleep apneas in a mouse model of Down syndrome

    by Manon Moreau, Amélia Madani, Rodolphe Dard, Nathaly Romero, Maud Ringot, Marie-Pia D'ORtho, Plamen Bokov, Nathalie Janel, Boris Matrot

    Severe obstructive sleep apnea is prevalent in neonates with Down syndrome, but neonatal breathing disorders remain unexplored in mouse models. Using the Dp(16)1Yey model, we observed prolonged obstructive apneas and lower heart rates at birth in mutant pups compared to wild-type littermates. This preclinical model provides a novel platform to study neonatal obstructive sleep apnea in Down syndrome and its contribution to neurodevelopmental disorders associated with Down syndrome.


  • Association of Snoring and Daytime Sleepiness With Subsequent Incident Hypertension: A Population-Based Cohort Study

    by Pauline Balagny, Emmanuelle Vidal-Petiot, Sofiane Kab, Justine Frija, Philippe Gabriel Steg, Marcel Goldberg, Marie Zins, Marie-Pia D’oRtho, Emmanuel Wiernik

    BACKGROUND: There is a strong association between obstructive sleep apnea and hypertension, but the effects of obstructive sleep apnea symptoms on the risk of incident hypertension are not well documented. The aim of this prospective study was to examine whether snoring and sleepiness are associated with incident hypertension. METHODS: Data from the French population-based CONSTANCES cohort were analyzed. Normotensive participants, aged 18 to 69 years, were included between 2012 and 2016 and screened for snoring, morning fatigue, and daytime sleepiness in 2017 using items of the Berlin Questionnaire. We used Cox models, adjusted for multiple potential confounders, including body mass index, baseline blood pressure, sleep duration, and depressive symptoms, to compute hazards ratios of incidentally treated hypertension. RESULTS: Among 34 727 subjects, the prevalence of self-reported habitual snoring, morning fatigue, and excessive daytime sleepiness (≥3× a week for each) was 23.6%, 16.6%, and 19.1%, respectively. During a median follow-up of 3.1 years (interquartile range, 3.0–3.5), the incidence of treated hypertension was 3.8%. The risk of de novo treated hypertension was higher in participants who reported habitual snoring (adjusted hazard ratio, 1.17 [95% CI, 1.03–1.32]) and excessive daytime sleepiness (adjusted hazard ratio, 1.42 [95% CI, 1.24–1.62]), and increased with the weekly frequency of symptoms, with a dose-dependent relationship ( P trend ≤0.02 for all symptoms). CONCLUSIONS: Self-reported snoring and excessive daytime sleepiness are associated with an increased risk of developing hypertension. Identification of snoring and daytime sleepiness may be a useful public health screening tool in primary care for hypertension prevention.


  • Open Access

    Academic and socio-professional trajectories in narcolepsy type 1: the NARCOSCOL-NARCOVITAE multicentric study

    by Laure Peter-Derex, Emmanuel Fort, Benjamin Putois, Nora Martel, François Ricordeau, Hélène Bastuji, Isabelle Arnulf, Lucie Barateau, Patrice Bourgin, Yves Dauvilliers, et al.

    Background and objectives Narcolepsy type 1 (NT1) is a chronic, disabling neurological disease. Sleep-related symptoms and comorbidities such as psycho-cognitive disturbances, and a frequent childhood onset of the disease may negatively impact patients’ career. We conducted a multicentric comparative cross-sectional study in Reference/Competence Centers for Narcolepsy in France to investigate the educational and occupational paths of patients with NT1. Methods Between February 2020 and 2023, adult patients with NT1 regularly followed-up in the participating centers were invited to complete online questionnaires including the Epworth sleepiness Scale, Narcolepsy Severity Scale, Beck Depression Inventory II, Siegrist questionnaire, Adult Self-Report and Adult Behavior Checklist, and a customized questionnaire on academic and professional trajectories. Controls were selected from within the patients’ close circle. Comparisons were adjusted for sex and age, and the determinants of patients’ professional prognosis were quantified by a composite score including professional-related outcomes. Results Questionnaires were filled by 235 patients (63.8% women, 36.4±14.7 years, 86.5% treated, 66.4% with childhood onset) and 166 controls (69.9% women, 40.3±14.4 years). No difference was observed between patients and controls for grade repetition and graduation level distribution, but patients reported more interruptions in their scolarity which was considered difficult, with more absenteeism and lateness. No difference was observed for employment rate (69.5% vs 77.0%) and socio-professional category distribution, but income was lower in patients who reported more unwanted changes in position and part-time work, with increased effort-reward imbalance (OR=2.28 95% CI [1.20-4.33], p=0.01). Almost half of the patients benefited from an official disability recognition and 10.2% received invalidity benefits. Impaired professional prognosis was associated with depression (pDiscussion Most patients with NT1 manage to achieve their careers goals, but at the cost of an effort/reward imbalance. Early diagnosis during childhood might allow a better adjustment to the disease. The critical role of co-morbidities in professional trajectories suggests that, in treated patients, psycho-cognitive disturbances have greater impact on daily functionning than sleep-related symptoms, and stresses the need to consider psycho-cognitivo-social dimensions in patient care.


  • Open Access

    Prevalence, treatment and determinants of obstructive sleep apnoea and its symptoms in a population-based French cohort

    by Pauline Balagny, Emmanuelle Vidal-Petiot, Adeline Renuy, Joane Matta, Justine Frija-Masson, Philippe Gabriel Steg, Marcel Goldberg, Marie Zins, Marie-Pia D'Ortho, Emmanuel Wiernik

    Background: Obstructive sleep apnoea (OSA) is associated with increased morbidity and mortality. Although the disorder has been well studied in selected high-risk populations, few data exist on its prevalence in the general population. We aimed to assess the prevalence and determinants of OSA in France.Methods: Data from participants of the French population-based CONSTANCES cohort aged 18–69 years at inclusion and being treated for sleep apnoea or screened for OSA in 2017 using the Berlin Questionnaire were analysed. Weighted analyses were performed to provide recent and representative results in the general population.Results: Among 20 151 participants, the prevalence of treated sleep apnoea was 3.5% (95% CI 3.0–3.9%). The prevalence of untreated subjects with a positive Berlin Questionnaire was 18.1% (95% CI 17.3–19.2%) for a total weighted prevalence of treated sleep apnoea or high risk of OSA of 20.9% (95% CI 20.0–21.9%). Regarding prevalence of OSA symptoms, it was 37.2% (95% CI 36.1–38.3%) for severe snoring and 14.6% (95% CI 13.8–15.5%) for hypersomnolence. In multivariable logistic regression analysis, male sex, age, previous cardiovascular events, smoking, low educational level, low physical activity and depressive symptoms were associated with having either treated sleep apnoea or a positive Berlin Questionnaire.Conclusion: In this large French population-based cohort, one in five participants had a high likelihood of OSA, whereas only 3.5% were treated for the disorder, suggesting major underdiagnosis in the general population. OSA diagnosis should be considered more often in people with risk factors such as depressive symptoms as well as unhealthy behaviours and socioeconomic conditions.


  • Open Access

    Continuous positive airway pressure as an accurate marker for non‐24‐hour sleep–wake rhythm disorder

    by Balthazar Bazin, Pierre A. Geoffroy, Hélène Benzaquen, Julia Maruani, Alix Romier, Michel Lejoyeux, Marie‐Pia D'ORtho, Justine Frija‐Masson

    Summary: Non‐24‐h sleep–wake rhythm disorder is quite rare in sighted patients and frequently associated with psychiatric disorders. We report the case of a 46‐year‐old man with autism spectrum disorder (ASD) and agoraphobia who had been referred for a suspicion of obstructive sleep apnea syndrome (OSAS). Polysomnography and arterial blood gas confirmed moderate OSAS associated with hypoventilation. Continuous positive airway pressure (CPAP) was started on fixed mode with excellent results. At follow‐up, his CPAP report data revealed an irregular sleep–wake rhythm with a progressive offset of sleep schedule and wake time delayed from 1 h from day to day. Melatonin (or agonist) is efficacious and safe for long‐term treatment in ASD and circadian rhythm sleep–wake disorder (CRSWD) with light therapy and wakefulness promoting medication. This case underlines the importance to sensitise psychiatrists to sleep and CRSWD, and also that CPAP data offer a possible objective alternative to sleep diary.